tiprankstipranks
pc:forxt

FoRx Therapeutics

FoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers. The company’s lead product candidate, FORX-428, is an oral small-molecule PARG inhibitor in Phase 1 development for advanced solid tumors, aimed at treating cancers resistant to PARP inhibitors.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 18, 2025
Series A
$50.00M

Investors

Investor Name
Funding Round

Related News and Analysis